Literature DB >> 17205026

Perflubron dosing affects ventilator-induced lung injury in rats with previous lung injury.

Jean-Damien Ricard1, Franck Iserin, Didier Dreyfuss, Georges Saumon.   

Abstract

OBJECTIVES: Randomized controlled trials of partial liquid ventilation in acute respiratory distress syndrome have been negative. Reasons for this failure may reside in the use of too large doses of perfluorocarbon. The objective was to evaluate whether various doses of perflubron affect ventilation-induced injury in edematous lungs in different ways.
DESIGN: Prospective, controlled animal study.
SETTING: Research laboratory of a university.
SUBJECTS: Male Wistar rats weighing 300+/-20 g.
INTERVENTIONS: Separate groups of rats were injected with alpha-naphtylthiourea to produce mild permeability pulmonary edema. They were then given 0, 7 (low), 13 (moderate), or 20 mL/kg (near functional residual capacity) perflubron doses and mechanically ventilated with a large (33 mL/kg) tidal volume for 15 mins.
MEASUREMENTS AND MAIN RESULTS: 125I-albumin distribution space was used to assess lung microvascular permeability. Quasi-static respiratory system pressure-volume curves were analyzed. Administration of low and moderate perflubron doses significantly improved respiratory mechanics and reduced the ventilator-induced permeability alterations to the level observed in rats that were not ventilated. By contrast, a perflubron dose that was near functional residual capacity increased end-inspiratory plateau pressure and aggravated the permeability alterations due to high tidal volume ventilation.
CONCLUSIONS: Near functional residual capacity but not low perflubron dose worsens ventilation-induced lung injury of preinjured lungs. This may provide some explanation for the negative results of the recent clinical trials, and it stresses the importance of the amount of perflubron used for partial liquid ventilation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17205026     DOI: 10.1097/01.CCM.0000253396.86212.8C

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  3 in total

1.  Characterization of a reverse-phase perfluorocarbon emulsion for the pulmonary delivery of tobramycin.

Authors:  Ryan A Orizondo; Charlene Irvin Babcock; Mario L Fabiilli; Leonid Pavlovsky; J Brian Fowlkes; John G Younger; Keith E Cook
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-01-29       Impact factor: 2.849

2.  Evaluation of lung recovery after static administration of three different perfluorocarbons in pigs.

Authors:  Mourad Chenoune; Ludovic De Rochefort; Patrick Bruneval; Fanny Lidouren; Matthias Kohlhauer; Aurélien Seemann; Bijan Ghaleh; Matthias Korn; Rose-Marie Dubuisson; Anis Ben Yahmed; Xavier Maître; Daniel Isabey; Jean-Damien Ricard; Richard E Kerber; Luc Darrasse; Alain Berdeaux; Renaud Tissier
Journal:  BMC Pharmacol Toxicol       Date:  2014-09-25       Impact factor: 2.483

3.  Hypothermic total liquid ventilation after experimental aspiration-associated acute respiratory distress syndrome.

Authors:  Jérôme Rambaud; Fanny Lidouren; Michaël Sage; Matthias Kohlhauer; Mathieu Nadeau; Étienne Fortin-Pellerin; Philippe Micheau; Luca Zilberstein; Nicolas Mongardon; Jean-Damien Ricard; Megumi Terada; Patrick Bruneval; Alain Berdeaux; Bijan Ghaleh; Hervé Walti; Renaud Tissier
Journal:  Ann Intensive Care       Date:  2018-05-02       Impact factor: 6.925

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.